Silexion Therapeutics Files 8-K, Notes Warrants

Ticker: SLXNW · Form: 8-K · Filed: Mar 28, 2025 · CIK: 2022416

Sentiment: neutral

Topics: corporate-action, warrants, filing

TL;DR

Silexion Therapeutics filed an 8-K on 3/28/25, formerly Biomotion Sciences, with warrants outstanding.

AI Summary

Silexion Therapeutics Corp. filed an 8-K on March 28, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Sciences until May 6, 2024, is incorporated in the Cayman Islands and has its principal executive offices in Ramat-Gan, Israel. The filing also notes the existence of warrants exercisable for ordinary shares at $1.150 per share.

Why It Matters

This filing provides an update on Silexion Therapeutics' corporate activities and financial reporting, including details about outstanding warrants which could impact future share structure and dilution.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report for Silexion Therapeutics Corp., detailing other events and financial statements, and noting the existence of warrants.

When did Silexion Therapeutics Corp. change its name?

Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, with the name change occurring on May 6, 2024.

What is the exercise price for the company's warrants?

The warrants are exercisable for ordinary shares at an exercise price of $1.150 per share.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

The company's principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.

What is the company's jurisdiction of incorporation?

Silexion Therapeutics Corp. is incorporated in the Cayman Islands.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing